This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Optimizing the Management of <em>Clostridium difficile</em> Infection (CDI)

Optimizing the Management of Clostridium difficile Infection (CDI)

Format

Patient Case Study

Time to Complete

30 minutes

Released

November 30, 2018

Expires

November 30, 2019
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 CreditsTM
0.50 / CE for Pharmacists (0.05 CEUs)

Accredited Provider



Provided by the Academy for Continued Healthcare Learning (ACHL).

Commercial Supporter

Supported by an educational grant from Merck & Company.

Program Description

Recorded at a prominent infectious-disease conference in October 2018, Carlene Muto, MD and Sahil Khanna, MBBS discuss new clinical practice guidelines from IDSA/SHEA and clinical best practices for optimal treatment of C. difficile infection. A C. difficile patient and survivor of 8 infection recurrences (9 total infections) also presents her story for expert panel discussion/analysis and audience questions. The purpose of this activity is to update physicians and pharmacists on the 2017 IDSA/SHEA guidelines for the treatment of Clostridium difficile infection and its recurrence.

Agenda

  • 1. Therapeutic selection under 2018 IDSA/SHEA C. difficile Guidelines for Kathy, a patient with eight CDI recurrent infections
  • 2. New practice guideline changes
  • 3. Emerging treatment paradigms/research pipeline

Intended Audience

This activity is intended for gastroenterologists, infectious disease specialists, pharmacists and other healthcare professionals that treat Clostridium difficile infection.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Outline patient and clinical factors that may predict C. difficile recurrence and implement effective tools/processes to identify at-risk patients.
  • Compare and contrast evidence-based approaches for the management of first and second recurrences of C. difficile infection in diverse patient populations, and appropriate targeted therapeutic selections for each.
  • Discuss newly released IDSA/SHEA clinical practice guidelines for C. difficile infection and how they compare with established practice patterns.

Pharmacy Educational Objectives
Upon completion of this activity, participants will be able to:

  • Outline patient and clinical factors that may predict C. difficile recurrence and implement effective tools/processes to identify at-risk patients.
  • Compare and contrast evidence-based approaches for medication therapy management (MTM) of first and second recurrences of C. difficile infection.
  • Discuss newly released IDSA/SHEA clinical practice guidelines for C. difficile infection and how they may affect existing antimicrobial stewardship protocols

Conflict Of Interest Disclosure Policy

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

Faculty

Sahil Khanna, MBBS
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota

Dr. Khanna discloses the following:
Advisory Board: Merck & Company
Consultant: Premier, Inc., Probiotech, LLC, and Shire PLC
Research Support: Rebiotix, Inc.

Carlene Muto, MD, MS
Associate Professor
Department of Medicine, Infectious Diseases
University of Virginia
Charlottesville, Virginia

Dr. Muto has no relevant financial relationships to disclose.

In collaboration with: Kathy, a CDI survivor of eight recurrent infections.

Kathy has no relevant financial relationships to disclose.

Accredited Provider Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

0.50

Type

CE for Pharmacists

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

This activity has been approved for 0.50 contact hours (0.05 CEUs).
ACPE Universal Activity Number: 0396-0000-18-070-H01-P
Activity Type: Knowledge

Disclosure of Unlabeled Use

This CME/CPE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CPE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Instructions

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate. CPE credit will be submitted to CPE Monitor® on the first day of each month.

If you have any questions relating to the accreditation of this activity, please contact:
Katlyn Cooper
kcooper@achlcme.org

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue